Linagliptin +pharma

Linagliptin, the active ingredient in Linagliptin +pharma, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving glycaemic control when combined with diet and exercise.

GNH USA supplies Linagliptin +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. It works across several therapeutic scenarios: - Type 2 diabetes mellitus (initial therapy): lowers HbA1c and fasting glucose as a first‑line oral agent. - Type 2 diabetes mellitus (add‑on therapy): enhances glycaemic control when combined with metformin or other oral antidiabetics. - Type 2 diabetes mellitus in renal impairment: provides glucose‑lowering effect without the need for dose adjustment in mild to moderate renal dysfunction.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Dizziness: occasional light‑headed sensation. - Gastrointestinal upset: nausea, abdominal discomfort or diarrhoea. - Back pain: intermittent musculoskeletal discomfort. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angio‑edema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Severe hypoglycaemia: when used with insulin or sulfonylureas.

Before initiating Linagliptin, clinicians should consider several safety aspects. - Renal function: monitor regularly; dose adjustment is not required but caution is advised in severe impairment. - Hepatic impairment: use with caution and monitor liver enzymes. - Hypoglycaemia risk: avoid concurrent use with insulin or sulfonylureas without dose adjustment. - Pancreatitis: discontinue if persistent abdominal pain occurs. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Linagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concomitant insulin or sulfonylureas: heightened risk of hypoglycaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase Linagliptin exposure. - Rifampin or other enzyme inducers: may reduce therapeutic effect.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors: monitor renal function and potassium levels. - Diuretics: watch for electrolyte disturbances. - Warfarin: periodic INR monitoring is advisable.